Research ArticleArticle
Timing and Magnitude of Initial Change in Disease Activity Score 28 Predicts the Likelihood of Achieving Low Disease Activity at 1 Year in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol: A Post-hoc Analysis of the RAPID 1 Trial
DÉSIRÉE VAN DER HEIJDE, EDWARD C. KEYSTONE, JEFFREY R. CURTIS, ROBERT B. LANDEWÉ, MICHAEL H. SCHIFF, DINESH KHANNA, TORE K. KVIEN, LUCIAN IONESCU, LEON M. GERVITZ, OWEN R. DAVIES, KRISTEL LUIJTENS and DANIEL E. FURST
The Journal of Rheumatology July 2012, 39 (7) 1326-1333; DOI: https://doi.org/10.3899/jrheum.111171
DÉSIRÉE VAN DER HEIJDE
EDWARD C. KEYSTONE
JEFFREY R. CURTIS
ROBERT B. LANDEWÉ
MICHAEL H. SCHIFF
DINESH KHANNA
TORE K. KVIEN
LUCIAN IONESCU
LEON M. GERVITZ
OWEN R. DAVIES
KRISTEL LUIJTENS
REFERENCES
- 1.↵
- Knevel R,
- Schoels M,
- Huizinga TW,
- Aletaha D,
- Burmester GR,
- Combe B,
- et al.
- 2.↵
- Smolen JS,
- Landewé R,
- Breedveld FC,
- Dougados M,
- Emery P,
- Gaujoux-Viala C,
- et al.
- 3.↵
- 4.↵
- 5.↵
- Gulfe A,
- Kristensen LE,
- Geborek P
- 6.↵
- Schiff M,
- Keystone E,
- Kvien T,
- Curtis J,
- Emery P,
- Luijtens K,
- et al.
- 7.↵
- Ichikawa Y,
- Saito T,
- Yamanaka H,
- Akizuki M,
- Kondo H,
- Kobayashi S,
- et al; and
- Study Group for the Japanese Ministry of Health, Labor and Welfare. Research for Establishment of Therapeutic Guidelines in Early Rheumatoid Arthritis Program
- 8.↵
- Keystone EC,
- Curtis JR,
- Fleischmann RM,
- Furst DE,
- Khanna D,
- Smolen JS,
- et al.
- 9.↵
- Keystone E,
- van der Heijde D,
- Mason D Jr.,
- Landewé R,
- Vollenhoven RV,
- Combe B,
- et al.
- 10.↵
- Felson DT,
- Smolen JS,
- Wells G,
- Zhang B,
- van Tuyl LH,
- Funovits J,
- et al.
- 11.↵
- Smolen JS,
- Aletaha D,
- Bijlsma JW,
- Breedveld FC,
- Boumpas D,
- Burmester G,
- et al; and
- T2T Expert Committee
In this issue
The Journal of Rheumatology
Vol. 39, Issue 7
1 Jul 2012
Timing and Magnitude of Initial Change in Disease Activity Score 28 Predicts the Likelihood of Achieving Low Disease Activity at 1 Year in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol: A Post-hoc Analysis of the RAPID 1 Trial
DÉSIRÉE VAN DER HEIJDE, EDWARD C. KEYSTONE, JEFFREY R. CURTIS, ROBERT B. LANDEWÉ, MICHAEL H. SCHIFF, DINESH KHANNA, TORE K. KVIEN, LUCIAN IONESCU, LEON M. GERVITZ, OWEN R. DAVIES, KRISTEL LUIJTENS, DANIEL E. FURST
The Journal of Rheumatology Jul 2012, 39 (7) 1326-1333; DOI: 10.3899/jrheum.111171
Timing and Magnitude of Initial Change in Disease Activity Score 28 Predicts the Likelihood of Achieving Low Disease Activity at 1 Year in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol: A Post-hoc Analysis of the RAPID 1 Trial
DÉSIRÉE VAN DER HEIJDE, EDWARD C. KEYSTONE, JEFFREY R. CURTIS, ROBERT B. LANDEWÉ, MICHAEL H. SCHIFF, DINESH KHANNA, TORE K. KVIEN, LUCIAN IONESCU, LEON M. GERVITZ, OWEN R. DAVIES, KRISTEL LUIJTENS, DANIEL E. FURST
The Journal of Rheumatology Jul 2012, 39 (7) 1326-1333; DOI: 10.3899/jrheum.111171